## Diagnosis: Ménière's Disease The triad of episodic vertigo, fluctuating hearing loss, and tinnitus with low-frequency SNHL on audiometry is pathognomonic for Ménière's disease (endolymphatic hydrops). ### Drug of Choice for Acute Symptom Management: Betahistine **Key Point:** Among the options provided, **Betahistine** is the most widely accepted and evidence-based drug for managing acute symptoms in Ménière's disease. It is the drug of choice per standard ENT references including Scott-Brown's Otorhinolaryngology and Indian ENT guidelines (AIIMS/PGIMER protocols). **Mechanism of Action:** - Partial H1-agonist and potent H3-antagonist on vestibular nuclei - Improves microcirculation in the stria vascularis and cochlea - Reduces endolymphatic pressure (hydrops) - Suppresses vestibular neurotransmission, providing symptomatic relief during acute attacks **Dosing:** 8–16 mg three times daily; higher doses (48 mg/day) used in acute/severe attacks **Clinical Pearl:** Betahistine (Serc) is the single most prescribed drug for Ménière's disease globally and in India, used both for acute attack management and long-term prophylaxis. It is the only drug with a dual role — providing acute relief AND addressing the underlying endolymphatic hydrops. Among the four options given, it is the best answer for "drug of choice for acute symptom management." ### Why Not the Other Options? | Drug | Role | Why Not First Choice Here | |------|------|--------------------------| | **Betahistine** | **Acute + prophylaxis** | **Correct — dual role, DOC in Ménière's** | | Diuretics (HCTZ + amiloride) | Long-term prophylaxis only | Reduces endolymphatic fluid volume over weeks; not for acute relief | | Cinnarizine | Vestibular suppressant | Symptomatic only; not disease-modifying; not universally first-line in Indian guidelines | | Corticosteroids | Intratympanic (refractory cases) | Reserved for refractory/severe disease; not first-line acute DOC | ### Management Strategy in Ménière's Disease - **Acute attack** → Betahistine (DOC); adjuncts: prochlorperazine or dimenhydrinate for nausea/vomiting - **Long-term prophylaxis** → Betahistine + Diuretics (HCTZ + amiloride) - **Refractory disease** → Intratympanic corticosteroids or gentamicin ### Why Low-Frequency SNHL? Ménière's disease characteristically causes low-frequency SNHL (250–1000 Hz) due to cochlear hydrops affecting the apical turn of the cochlea (which encodes low frequencies). This distinguishes it from presbycusis (high-frequency loss) and noise-induced SNHL (4 kHz notch). **High-Yield (Scott-Brown / Dhingra ENT):** Betahistine is the drug of choice in Ménière's disease. It reduces the frequency and severity of acute attacks and is used as first-line pharmacotherapy in both acute and prophylactic settings. **Warning:** Corticosteroids are NOT the first-line drug of choice for acute Ménière's attacks; they are reserved for intratympanic use in refractory cases. Diuretics are prophylactic agents, not acute-attack drugs.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.